Review

Transactivation of Genes Encoding for Phase II Enzymes and Phase III Transporters by Phytochemical Antioxidants

Yoon Mee Yang, Kyoung Noh, Chang Yeob Han and Sang Geon Kim *

Innovative Drug Research Center for Metabolic and Inflammatory Disease, College of Pharmacy, Seoul National University, Gwanak-ro 599, Seoul 151-742, Korea

* Author to whom correspondence should be addressed; E-Mail: sgk@snu.ac.kr; Tel.: +82-2-880-7840; Fax: +82-2-872-1795.

Received: 6 August 2010; in revised form: 31 August 2010 / Accepted: 3 September 2010 / Published: 7 September 2010

Abstract: The induction of phase II enzymes and phase III transporters contributes to the metabolism, detoxification of xenobiotics, antioxidant capacity, redox homeostasis and cell viability. Transactivation of the genes that encode for phase II enzymes and phase III transporters is coordinatively regulated by activating transcription factors in response to external stimuli. Comprehensive studies indicate that antioxidant phytochemicals promote the induction of phase II enzymes and/or phase III transporters through various signaling pathways, including phosphoinositide 3-kinase, protein kinase C, and mitogen-activated protein kinases. This paper focuses on the molecular mechanisms and signaling pathways responsible for the transactivation of genes encoding for these proteins, as orchestrated by a series of transcription factors and related signaling components.

Keywords: phase 2 enzyme; phase 3 transporter; NF-E2-related factor 2; CCAAT-enhancer binding protein-β; hepatic nuclear factor; farnesoid X receptor

1. Introduction

Biotransformation of xenobiotics including drugs is catalyzed by enzymes which are commonly referred to as drug-metabolizing enzymes. Most tissues and organs have detoxifying systems responsible for the transformation and removal of chemicals. Proteins, which include phase I, phase II enzymes and phase III transporters, play key roles in the metabolism, detoxification, and/or
elimination of exogenous chemicals introduced into the body as well as endogenous ones [1,2]. The metabolizing enzymes are basally expressed and/or induced by external stimuli. In addition, diverse phytochemicals have beneficial actions by upregulating them.

1.1. Phase II enzyme induction

Phase II enzymes such as UDP-glucuronosyl transferases, glutathione S-transferases (GSTs), NAD(P)H:quinone oxidoreductases (NQOs), and N-acetyltransferases catalyze conjugation reactions of exogenous and endogenous chemicals, usually after phase I reactions (i.e., oxidation, reduction and hydrolysis) [1]. In general, they mediate detoxification and elimination of toxicants through diverse reactions (e.g., glucuronidation, sulfation, acetylation and methylation), whereas phase I oxidation reactions may often produce reactive metabolites. If the conjugation reactions are inadequate, active metabolites may cause damage and injury to cells and tissues, which is frequently accompanied by inflammatory responses [3]. Thus, the inducers of phase II enzymes have cytoprotective effects.

1.2. Phase III transporter induction

Phase III transporters are expressed in many tissues, including the liver, intestine, kidney and brain, where they provide a barrier against drug penetration, acting as the major determinants of the systemic bioavailability of many drugs (e.g., absorption, distribution and excretion) [4,5]. P-glycoprotein (P-gp) and multidrug resistant-associated protein (MRP) transport a broad range of substrates across the cell membrane by utilizing the energy released from ATP hydrolysis [4]. The ATP-binding cassette (ABC) transporters either import or export various substrates such as sugars, amino acids, lipids, ions, xenobiotics and many therapeutic agents [6,7]; they have two nucleotide binding domains and two transmembrane domains. The nucleotide binding domain, also called as an ABC, is the main characteristic of transporter family, and the transmembrane domain facilitates the movement of substrates across the cell membranes [6,7].

In humans, 46 ABC transporters have been identified [4,6]. Along with P-gp (or MDR1; ABCB1), the MDR subfamily includes MDR3 (ABCB4), and bile salt export protein (Bsep or SP-gp; ABCB11) [8]. The MRP subfamily consists of nine subfamilies (MRP1-9) [6]. MRP1 (ABCC1) and MRP3 (ABCC3) are typically located on the basolateral membrane of polarized cells, whereas MRP2 (ABCC2) mostly exists in the apical canalicular membrane, implying that MRP2-mediated transport increases excretion into bile, whereas MRP1/3-mediated transport does it into the urine. Organic anion transporting polypeptide 2 (OATP2), localized in the hepatic sinusoidal membrane, mediates ATP- and sodium-independent transport of compounds, including bilirubin, steroids, type II organic cations, thyroid hormones and bile salts [9,10]. P-gp, MRP and OATP2 that are expressed on the membrane of the intestinal enterocytes excrete xenobiotics into the lumen [7,11].

In response to various extracellular stimuli, the transactivation of phase II enzyme and phase III transporter genes is coordinately regulated by activating transcription factors. This paper focuses on the molecular mechanisms of transcriptional induction of the genes orchestrated by a series of transcriptional factors.
2. Transcription Factors that Promote Phase II and Phase III Gene Induction

2.1. NF-E2-related factor 2 (Nrf2)

Nrf2 is a Cap’n’Collar/basic leucine zipper transcription factor. In the resting state, Keap1 interacts with Nrf2 for its degradation by Cullin 3-mediated ubiquitination in the cytoplasm [12]. When Keap1 dissociates from Nrf2 under oxidative and xenobiotic stress, Nrf2 is phosphorylated and translocated into the nucleus [13]. Unlike canonical bZIP proteins, Nrf2 can not form homodimer [14]. It forms a heterodimer with small Maf proteins (e.g., MafF/G/K) that lack a canonical transactivation domain.

The induction of phase II enzymes and phase III transporters depends on the activity of Nrf2. Major anti-oxidant enzymes contain one or more functional antioxidant response elements (AREs) in their promoter regions. Once Nrf2 dissociates from its Keap1 binding in response to oxidative stress, it translocates into the nucleus and binds ARE in the target genes. Thus, Nrf2 activation transactivates the genes containing ARE(s) such as GST, heme oxygenases-1 (HO-1), UDP-glucuronosyl transferase, NQO-1, $\gamma$-glutamylcysteine synthetase and organic anion transporters [12]. Nrf2 activation and gene induction contribute to the detoxification and excretion of xenobiotics. Plant or synthetic chemicals may have cytoprotective and chemopreventive effects by activating Nrf2 [15]. Consistently, a deficiency in Nrf2 abrogates the abilities of these agents to protect cells from toxicant or other stresses.

2.2. CCAAT-enhancer binding protein-β (C/EBPβ)

Among the members of C/EBP family, C/EBPβ is a transcription factor responsible for the expression of genes encoding for antioxidant and/or conjugating enzymes [16]. It binds to a C/EBP-binding site as homo- or heterodimers. The localization and/or activity of C/EBPβ can be regulated by phosphorylation. C/EBPβ is phosphorylated by p90 ribosomal S6 kinase-1 (RSK1) and translocated from the cytoplasm into the nucleus [17]. Once in the nucleus, a phosphorylated form binds the C/EBP-response element [18]. Ceramide, a toxic lipid, decreased the transcriptional activity of C/EBPβ by reducing its phosphorylation [19]. In contrast, treatment of hepatocytes with oltipraz, a cancer chemopreventive agent, activated and induced C/EBPβ. The activation of C/EBPβ led to phase II enzyme induction, contributing to its antioxidant effect [20]. Prostaglandin J2 treatment also induces GSTA2 by activating C/EBPβ as well as Nrf2 [21]. In most cases, the expression of phase II genes may be coordinately regulated by C/EBPβ and Nrf2 that make a large enhanceosome complex.

2.3. Hepatic nuclear factor 1 (HNF1)

HNF1, a liver-specific gene transactivator, is a dimeric transcription regulator. HNF1α, but not HNF1β, exists in hepatocytes [22] and is also expressed in other tissues including kidney, intestine and pancreatic islets [23]. The binding of HNF1α to the cis-acting HNF1-binding element in the target promoters regulates the expression of genes including glucose-6-phosphatase, albumin, $\alpha$-lipoprotein AII and B, and CYP2E1 [22,24]. The transcriptional activity of HNFs is regulated by coactivators such as CBP, p300 and p300/CBP-associated factor [22]. Several reports have suggested the important role of HNF1 in cell survival. So, HNF1α deficiency causes hepatic dysfunction [25]; inhibition of HNF1α triggers mitochondrial hyperpolarization and apoptotic cell death in response to toxic stimuli (e.g.,
ceramide) [26]. For example, ceramide enhances the degradation of HNF1 [27], which might cause apoptosis. Furthermore, HNF recognition element has been identified in the promoter region of the GSTA2 gene [28]. Oltipraz treatment increased the nuclear accumulation and DNA binding of HNF1 [27], indicating that the activation of HNF1 might contribute to its cytoprotective effect. HNF1α is a master regulator of several transporter families. HNF1α disruption results in significant downregulation of several organic anion transporters (Oat) and Oatp uptake transporters in liver and kidney, but increases the expression of efflux transporters (e.g., MDR and MRP) [29].

Liver-enriched HNF4α promotes the expression of genes involved in hepatic lipid homeostasis and hepatocyte differentiation [30,31]. It also regulates the expression of phase II enzymes and phase III transporters (e.g., UGT1A9) [32]. In addition, HNF4α, not HNF1α, binds to the Ntcp promoter. The HNF4α binding site located in the human steroid- and bile acid-sulfotransferase gene enhances basal promoter activity [33]. In fasted rats, HNF4α upregulates the basolateral bile acid transporters (e.g., Ntcp, Oatp1, and Oatp2) [34].

2.4. Peroxisome proliferator-activated receptors (PPARs)

Currently, three members of this nuclear receptor family have been identified, namely PPARα, PPARβ and PPARγ [35,36]. PPARα is expressed in the liver, heart, kidney, intestine and brown adipose tissue. PPARβ is expressed in most adult tissues; brain, kidney and intestine are the highest expressed tissues. PPARγ, mainly expressed in the spleen, intestine and fat cells, is composed of two submembers, PPARγ1 and PPARγ2. PPARs regulate physiological functions such as lipoprotein and fatty acid metabolism [1,2,36-38]. In the GSTA2 gene, a PPAR-binding site cluster was identified. In particular, specific mutations in the peroxisome proliferator response element (PPRE) sites caused defect in the responsiveness [21]. PPARγ and retinoid X receptor (RXR) activate the GSTA2 gene [21]. In addition, the PPARγ agonist and 9-cis retinoic acid synergistically enhanced the activities of Nrf2 and C/EBPβ [21].

2.5. Nuclear receptors [pregnane X receptor (PXR), farnesoid X receptor (FXR)]

The expression of phase III transporters such as P-gp, depends on PXR [39,40]. PXR ligands including rifampicin, clotrimazole, mifepristone and nifedipine induced MDR1 gene in hepatocytes and cancer cells [2,41,42]. Constitutively activated hPXR also induces P-gp without specific ligand binding. A direct repeat 4 nuclear receptor response element was identified as a distinct PXR binding site essential for MDR1 induction by rifampicin [43]. In addition, PXR activation causes the induction of other transporters including OATP2 [44,45], MRP2 [46] and MRP3 [47,48].

FXR (NR1H4) is expressed in liver, intestine, kidney and adrenal glands [49-51]. Bile acids including chenodeoxycholic acid are endogenous ligands of the receptor [52]. FXR has diverse physiological roles in the regulation of bile acid, lipid and glucose metabolism. As a transcription factor, it regulates the expression of genes including hepatic transporters; Bsep, MRP2 (ABCC2) and MDR3 (ABCB4) are present in the bile canalicular membrane and thereby help secrete bile acids (and other compounds) [53,54]. FXR also controls the process of bile acid absorption via apical sodium-dependent bile acid transporter, heterodimeric organic solute transporter-α and -β. Thus, FXR is a key
sensor for bile acids and plays a role in maintaining bile acid homeostasis such as bile acid synthesis, conjugation, secretion and absorption.

2.6. Cooperative interactions of activating transcription factors

Diverse transcription factors cooperatively regulate the expression of phase II and/or phase III enzymes. The GSTA2 gene transactivation is controlled by both the ARE and C/EBP-binding sites [21]. A deletion of either ARE or C/EBP-binding sites prevented the PPARγ and RXRα-mediated GSTA2 gene induction, indicating that Nrf2 and C/EBPβ binding to their responsive DNA elements are essential for full transactivation of the gene. In addition, the ligand-dependent transcriptional activity was inhibited by a mutation of the respective PPRE binding site [21], suggesting that the PPREs are important for the full ligand responsiveness. Thus, protein complex formation on target DNA binding site seems to be an important step for transcriptional activation by inducers.

3. The Signaling Pathways for Transcription Factor Activation

3.1. Phosphatidylinositol 3-kinase (PI3K)

PI3K phosphorylates phosphatidylinositols at the 3 position of the inositol ring, and the downstream Akt-p70S6 kinase pathway regulates a variety of biological responses including cell proliferation, survival, mitogenesis and cell transformation [55]. PI3K has been reported to act as a positive regulator of Nrf2 binding with ARE [56] (Figure 1). Kang et al. showed that PI3K is involved in nuclear localization of Nrf2 by tert-butylhydroquinone-induced oxidative stress, and is associated with cytoplasmic actin rearrangement [57].

Figure 1. The signaling pathways for transcription factor activation that leads to phase II enzyme and phase III transporter induction.
Insulin stimulates Nrf2 activity and induces GSTA2 [57]. Since Akt and RSK1, the downstream molecules of PI3K, are activated by insulin, the induction of GSTA2 may depend on the activation of mTOR complex. The finding that ceramide decreased S6K1 activity and protein synthesis [58] indicates that ceramide inhibits GSTA2 expression [59] at least in part through the repression of the mTOR pathway. Thus, mTOR signaling may be involved in the regulation of GST expression. Insulin also activates C/EBPs via PI3K [60]. Likewise, α-lipoic acid treatment induced phase II enzymes through PI3K-dependent activation of C/EBPα and C/EBPβ, enhancing the ability of insulin to induce target genes [20] (Figure 1). In addition, the activation of C/EBPβ by oltipraz and its metabolites contributes to the induction of phase II genes in a PI3K-dependent manner [18,61].

3.2. Protein kinase C (PKC)

PKCs consist of 12 isoforms of the PKC family, which are grouped into 3 subfamilies based on their second messenger requirements: 1) conventional (PKCα, PKCβI, PKCβII and PKCγ), 2) novel (PKCδ, PKCe, PKCη and PKCθ) and 3) atypical (PKCι, PKCζ, PK-N1 and PK-N2). Conventional PKCs require diacylglycerol phospholipase C, Ca2+ and phospholipid for activation. Novel PKCs require diacylglycerol phospholipase, but not Ca2+. Atypical PKCs require neither diacylglycerol phospholipase nor Ca2+. In some cells, PKCζ may be at downstream of PI3K, whose activation depends on PI3K products [62].

Nrf2 activation requires phosphorylation at serine-40 by PKCδ [63,64] (Figure 1): a mutant form of Nrf2 (S40A) could not be phosphorylated by PKC. This mutation affects the association of Nrf2 with Keap1, but not the in vitro binding of Nrf2/MafK to the ARE [63,64]. The phosphorylation of wild-type Nrf2 by PKCδ promotes its dissociation from Keap1, contributing to its stabilization. This finding indicates that PKCδ-induced Nrf2 phosphorylation is crucial for ARE-mediated antioxidant response. Treatment with PKC activator, phorbol 12-myristate 13-acetate, increased the phosphorylation of FXR. A study showed that the DNA binding domain of FXR was in vitro phosphorylated by PKCα and PKCβI [65] (Figure 1). The phosphorylation of FXR induced by PKCα directly modulates ligand-mediated regulation of FXR target genes. Consistently, the induction of FXR target genes by chenodeoxycholic acid was repressed by PKC inhibition, but not by PKA or PI3K inhibition. In addition, PKCζ directly phosphorylates FXR at threonine 442 site. So, PKCζ knockdown decreased its nuclear localization [66].

3.3. Mitogen-activated protein kinases (MAPKs)

Three major MAPK pathways [i.e., extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 kinase] are involved in the regulation of many transcription factors, which affects the phase II enzyme and phase III transporter expression (Figure 1). Nrf2 activity may be modulated by MAPKs [67]; ERK2, ERK5 and JNK1 increase ARE activation [68-70], whereas p38 kinase suppresses it [71].

C/EBPβ is regulated by the MAPK pathways. Interferon γ-stimulated pathway stimulates C/EBPβ-dependent gene expression via MEKK-MEK1-ERK1/2 and p38 kinase [72,73]. In addition, JNK inhibition reduced C/EBPβ expression, indicating that phosphorylation induced by JNK participates in C/EBPβ expression [74].
The transcriptional activity of HNF4α may be regulated by post-translational modifications. Thirteen potential serine/threonine phosphorylation sites exist in HNF4α. It is phosphorylated by kinases including p38 kinase, ERK1/2, PKA, PKB, PKC and AMPK, and the phosphorylated forms have lower DNA binding, dimerization or transactivation activities [75,76]. JNK1 phosphorylates HNF4α, and reduces its interaction with DNA. Of interest, HNF1α negatively regulates its own and HNF4 expressions by a negative feedback loop [77]. HNF1α expression in turn depends on HNF4α expression, and is reduced under the condition of reduced HNF4α activity [78-80].

The members of the RSK family play a role in mitogen-activated cell growth, differentiation, or cell survival. RSK1 is a major form expressed in the liver, muscle and fat [81]. RSK, a serine/threonine protein kinase, is activated by ERK [82]. It contains two distinct active kinase domains. Activated RSK1 phosphorylates C/EBPβ and CREB [83].

4. The Induction of Phase II Enzymes and/or Phase III Transporters by Antioxidant Phytochemicals

4.1. Genistein

Genistein, a biologically active isoflavone found in soy, has a chemopreventive effect. Genistein modulates the expression of genes encoding for phase II and antioxidant enzymes. Feeding rats with diets containing genistein stimulated hepatic NQO-1 activity. It increased hepatic GSTA2 mRNA level, but decreased those of GSTM2 and GSTP1 [84]. However, GST activity was decreased in the liver of mice fed 1,500 mg/kg of genistein [85]. Genistein treatment repressed sulfotransferase 1E1, UGT1A1, UGT2B7, UGT2B15, MRP2 and MRP4 mRNA levels [86].

4.2. Resveratrol

Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a natural polyphenol compound present in grapes and peanuts. This agent has a variety of potential therapeutic effects. Many of the beneficial effects of resveratrol are a result of its antioxidant action. Resveratrol scavenges not only lipid hydroperoxyl free radicals, but hydroxyl and superoxide anion radicals and thus, resveratrol treatment protects cells from oxidative stress by increasing Nrf2 activity through Akt/protein kinase B and ERK1/2 pathways [87].

Resveratrol alters the profile of xenobiotic-metabolizing enzyme activity; GST was significantly inhibited, particularly in the lung (~76% loss of activity) after single administration of 25 mg resveratrol/kg b.w. A different response for UDP-glucuronosyl transferase was observed; a significant induction was seen (83%) in the liver, whereas a significant reduction was observed in the lung (up to ~83% loss) after treatment with 25 mg resveratrol/kg b.w. for 7 days [88]. Resveratrol also regulates the expression of phase III transporters; it down-regulates MRP1 expression and thereby reverses doxorubicin resistance in acute myeloid leukemia cells [89].

4.3. Liquiritigenin

Liquiritigenin, a biologically active licorice component, inhibited LPS-induced NO synthase induction [90]. After intravenous administration of liquiritigenin, bile flow rate and biliary excretion of bile acid, glutathione and bilirubin contents were elevated [91]. Liquiritigenin treatment markedly
stimulated Nrf2 translocation into the nucleus via PKCδ activation [92]. The natural compound enhances not only the expression of hepatic phase II enzymes but that of canalicular efflux transporters and basolateral uptake transporters [91] (Figure 2). Consistently, liquiritigenin treatment attenuated galactosamine/LPS-induced hepatitis in rats [91]. Overall, liquiritigenin has a hepatoprotective effect by inducing phase II enzymes and phase III transporters.

**Figure 2.** The induction of phase II enzyme and phase III transporters by liquiritigenin.

---

### 4.4. Sauchinone

Sauchinone, a lignan from the roots of *Saururus chinensis* (Lour.) Baill, Saururaceae, has potent hepatoprotective and anti-inflammatory actions [93,94]. It also inhibits bone resorption [95]. In a cell culture model, sauchinone treatment induced HO-1 expression and activity, which in part accounts for its cytoprotective efficacy against oxidative injury [96]. Moreover, sauchinone enhanced nuclear accumulation of Nrf2, and increased ARE activity. Sauchinone protects cells from $t$-butylhydroperoxide-induced oxidative injury, possibly through p38 kinase-mediated Nrf2/ARE-dependent HO-1 induction [96].

### 4.5. Dithiolethiones

Oltipraz [4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione] is a synthetic compound that has the dithiolethione moiety found in the *Crucifera.* [97]. Dithiolethiones and some of their metabolites are inducers of genes encoding for phase II enzymes [18,61,98,99]. Oltipraz exerts its cancer chemopreventive effect by inducing these enzymes [100,101]. Nrf2 is critical for the enzyme induction
by oltipraz [98,102,103]. Also, oltipraz induced C/EBPβ [18,83], and antagonized the effect of hepatitis B virus X that represses C/EBPβ-mediated GST induction [104]. Phase III transporters are also induced by oltipraz treatment [105,106]. The effect of oltipraz on MRP expression is mediated with Nrf2 [105,106]. Thus, oltipraz’s actions seem to be cooperatively regulated by both Nrf2 and C/EBPβ.

5. Conclusions

Living organisms have their own defense mechanisms to protect themselves from cellular damage caused by oxidative stress. The ability of cells to maintain homeostasis during stress can be achieved by inducing detoxifying enzymes and transporters and consequently removing harmful substances. A battery of genes encoding for these proteins shares common transcriptional regulatory mechanism (Figure 3). Antioxidant phytochemicals activate signaling pathways responsible for the regulation of key transcription factors, thereby inducing phase II and phase III proteins for the improved metabolism and excretion of xenobiotics.

**Figure 3.** A schematic representation of the mechanism by which phytochemical induces target genes.

**Acknowledgments**

This research was supported by a grant (10182KFDA992) from Korea Food & Drug Administration in 2010.
References

1. Rushmore, T.H.; Kong, A.N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. *Curr. Drug Metab.* 2002, 3, 481-490.

2. Wang, H.; LeCluyse, E.L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. *Clin. Pharmacokinet.* 2003, 42, 1331-1357.

3. Mates, J.M. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. *Toxicology* 2000, 153, 83-104.

4. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. *Pharmacol. Rev.* 2003, 55, 425-461.

5. Staudinger, J.L.; Madan, A.; Carol, K.M.; Parkinson, A. Regulation of drug transporter gene expression by nuclear receptors. *Drug Metab. Dispos.* 2003, 31, 523-527.

6. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. *J. Lipid Res.* 2001, 42, 1007-1017.

7. Kerb, R.; Hoffmeyer, S.; Brinkmann, U. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRPI and MRP2. *Pharmacogenomics* 2001, 2, 51-64.

8. Brinkmann, U.; Eichelbaum, M. Polymorphisms in the ABC drug transporter gene MDR1. *Pharmacogenomics J.* 2001, 1, 59-64.

9. Reichel, C.; Gao, B.; Van Montfoort, J.; Cattori, V.; Rahner, C.; Hagenbuch, B.; Stieger, B.; Kamisako, T.; Meier, P.J. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. *Gastroenterology* 1999, 117, 688-695.

10. Shitara, Y.; Sugiyama, D.; Kusuhara, H.; Kato, Y.; Abe, T.; Meier, P.J.; Itoh, T.; Sugiyama, Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. *Pharm. Res.* 2002, 19, 147-153.

11. Kim, R.B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. *Eur. J. Clin. Invest.* 2003, 33 (Suppl. 2), 1-5.

12. Itoh, K.; Ishii, T.; Wakabayashi, N.; Yamamoto, M. Regulatory mechanisms of cellular response to oxidative stress. *Free Radical Res.* 1999, 31, 319-324.

13. Motohashi, H.; Yamamoto, M. Nrf2-Keap1 defines a physiologically important stress response mechanism. *Trends Mol. Med.* 2004, 10, 549-557.

14. Li, W.; Kong, A.N. Molecular mechanisms of Nrf2-mediated antioxidant response. *Mol. Carcinog.* 2009, 48, 91-104.

15. Eggler, A.L.; Gay, K.A.; Mesecar, A.D. Molecular mechanisms of natural products in chemoprevention: Induction of cytoprotective enzymes by Nrf2. *Mol. Nutr. Food Res.* 2008, 52 (Suppl 1), S84-S94.

16. Ramji, D.P.; Foka, P. CCAAT/enhancer-binding proteins: Structure, function and regulation. *Biochem. J.* 2002, 365, 561-575.

17. Buck, M.; Chojkier, M. Signal transduction in the liver: C/EBPbeta modulates cell proliferation and survival. *Hepatology* 2003, 37, 731-738.

18. Kang, K.W.; Cho, I.J.; Lee, C.H.; Kim, S.G. Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz. *J. Natl. Cancer Inst.* 2003, 95, 53-66.
19. Sprott, K.M.; Chumley, M.J.; Hanson, J.M.; Dobrowsky, R.T. Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein beta during inhibition of adipogenesis by ceramide. *Biochem. J.* **2002**, *365*, 181-191.

20. Ki, S.H.; Kim, S.G. Phase II enzyme induction by alpha-lipoic acid through phosphatidylinositol 3-kinase-dependent C/EBPs activation. *Xenobiotica* **2008**, *38*, 587-604.

21. Park, E.Y.; Cho, I.J.; Kim, S.G. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. *Cancer Res.* **2004**, *64*, 3701-3713.

22. Schrem, H.; Klempnauer, J.; Borlak, J. Liver-enriched transcription factors in liver function and development. Part I: The hepatocyte nuclear factor network and liver-specific gene expression. *Pharmacol. Rev.* **2002**, *54*, 129-158.

23. Parrizas, M.; Maestro, M.A.; Boj, S.F.; Paniagua, A.; Casamitjana, R.; Gomis, R.; Rivera, F.; Ferrer, J. Hepatic nuclear factor 1-alpha directs nucleosomal hyperacetylation to its tissue-specific transcriptional targets. *Mol. Cell Biol.* **2001**, *21*, 3234-3243.

24. Borlak, J.; Thum, T. Induction of nuclear transcription factors, cytochrome P450 monooxygenases, and glutathione S-transferase alpha gene expression in Aroclor 1254-treated rat hepatocyte cultures. *Biochem. Pharmacol.* **2001**, *61*, 145-153.

25. Pontoglio, M.; Barra, J.; Hadchouel, M.; Doyen, A.; Kress, C.; Bach, J.P.; Babinet, C.; Yaniv, M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* **1996**, *84*, 575-585.

26. Wobser, H.; Dussmann, H.; Kogel, D.; Wang, H.; Reimertz, C.; Wollheim, C.B.; Byrne, M.M.; Prehn, J.H. Dominant-negative suppression of HNF-1 alpha results in mitochondrial dysfunction, INS-1 cell apoptosis, and increased sensitivity to ceramide-, but not to high glucose-induced cell death. *J. Biol. Chem.* **2002**, *277*, 6413-6421.

27. Park, I.N.; Cho, I.J.; Kim, S.G. Ceramide, an apoptotic rheostat, inhibits CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 activation: The role in glutathione S-transferase A2 gene repression. *Drug Metab. Dispos.* **2004**, *32*, 893-897.

28. Rushmore, T.H.; King, R.G.; Paulson, K.E.; Pickett, C.B. Regulation of glutathione S-transferase Ya subunit gene expression: Identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 3826-3830.

29. Maher, J.M.; Slitt, A.L.; Callaghan, T.N.; Cheng, X.; Cheung, C.; Gonzalez, F.J.; Klaassen, C.D. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. *Biochem. Pharmacol.* **2006**, *72*, 512-522.

30. Hayhurst, G.P.; Lee, Y.H.; Lambert, G.; Ward, J.M.; Gonzalez, F.J. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. *Mol. Cell Biol.* **2001**, *21*, 1393-1403.

31. Watt, A.J.; Garrison, W.D.; Duncan, S.A. HNF4: A central regulator of hepatocyte differentiation and function. *Hepatology* **2003**, *37*, 1249-1253.
32. Barbier, O.; Girard, H.; Inoue, Y.; Duez, H.; Villeneuve, L.; Kamiya, A.; Fruchart, J.C.; Guillemette, C.; Gonzalez, F.J.; Staels, B. Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. *Mol. Pharmacol.* **2005**, *67*, 241-249.

33. Echchgadda, I.; Song, C.S.; Oh, T.; Ahmed, M.; De La Cruz, I.J.; Chatterjee, B. The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase. *Mol. Endocrinol.* **2007**, *21*, 2099-2111.

34. Dietrich, C.G.; Martin, I.V.; Porn, A.C.; Voigt, S.; Gartung, C.; Trautwein, C.; Geier, A. Fasting induces basolateral uptake transporters of the SLC family in the liver via HNF4alpha and PGC1alpha. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2007**, *293*, G585-G590.

35. Gervois, P.; Torra, I.P.; Fruchart, J.C.; Staels, B. Regulation of lipid and lipoprotein metabolism by PPAR activators. *Clin. Chem. Lab. Med.* **2000**, *38*, 3-11.

36. Gilde, A.J.; van der Lee, K.A.; Willemsen, P.H.; Chinetti, G.; van der Leij, F.R.; van der Vusse, G.J.; Staels, B.; van Bilsen, M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. *Circ. Res.* **2003**, *92*, 518-524.

37. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature* **1990**, *347*, 645-650.

38. Tugwood, J.D.; Issemann, I.; Anderson, R.G.; Bundell, K.R.; McPheat, W.L.; Green, S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. *EMBO J.* **1992**, *11*, 433-439.

39. Johnson, B.M.; Charman, W.N.; Porter, C.J. Application of compartmental modeling to an examination of *in vitro* intestinal permeability data: Assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. *Drug Metab. Dispos.* **2003**, *31*, 1151-1160.

40. Perloff, M.D.; von Moltke, L.L.; Greenblatt, D.J. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. *Xenobiotica* **2004**, *34*, 133-150.

41. Kullak-Ublick, G.A.; Becker, M.B. Regulation of drug and bile salt transporters in liver and intestine. *Drug Metab. Rev.* **2003**, *35*, 305-317.

42. Song, X.; Xie, M.; Zhang, H.; Li, Y.; Sachdeva, K.; Yan, B. The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. *Drug Metab. Dispos.* **2004**, *32*, 35-42.

43. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. *J. Biol. Chem.* **2001**, *276*, 14581-14587.

44. Staudinger, J.; Liu, Y.; Madan, A.; Habeebu, S.; Klaassen, C.D. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. *Drug Metab Dispos* **2001**, *29*, 1467-1472.

45. Staudinger, J.L.; Goodwin, B.; Jones, S.A.; Hawkins-Brown, D.; MacKenzie, K.I.; LaTour, A.; Liu, Y.; Klaassen, C.D.; Brown, K.K.; Reinhard, J.; Willson, T.M.; Koller, B.H.; Kliewer, S.A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 3369-3374.
46. Kast, H.R.; Goodwin, B.; Tarr, P.T.; Jones, S.A.; Anisfeld, A.M.; Stoltz, C.M.; Tontonoz, P.; Kliwer, S.; Willson, T.M.; Edwards, P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. *J. Biol. Chem.** 2002, **277**, 2908-2915.

47. Kullak-Ublick, G.A.; Stieger, B.; Meier, P.J. Enterohepatic bile salt transporters in normal physiology and liver disease. *Gastroenterology** 2004, **126**, 322-342.

48. Teng, S.; Jekerle, V.; Piquette-Miller, M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. *Drug Metab. Dispos.** 2003, **31**, 1296-1299.

49. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, R.M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell** 1995, **81**, 687-693.

50. Huber, R.M.; Murphy, K.; Miao, B.; Link, J.R.; Cunningham, M.R.; Rupar, M.J.; Gunyuzlu, P.L.; Haws, T.F.; Kassam, A.; Powell, F.; Hollis, G.F.; Young, P.R.; Mukherjee, R.; Burn, T.C. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. *Gene** 2002, **290**, 35-43.

51. Zhang, Y.; Kast-Woelbern, H.R.; Edwards, P.A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. *J. Biol. Chem.** 2003, **278**, 104-110.

52. Wang, H.; Chen, J.; Hollister, K.; Sowers, L.C.; Forman, B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol. Cell** 1999, **3**, 543-553.

53. Lee, F.Y.; Lee, H.; Hubbert, M.L.; Edwards, P.A.; Zhang, Y. FXR, a multipurpose nuclear receptor. *Trends Biochem. Sci.** 2006, **31**, 572-580.

54. Kalaany, N.Y.; Mangelsdorf, D.J. LXRS and FXR: The yin and yang of cholesterol and fat metabolism. *Annu. Rev. Physiol.** 2006, **68**, 159-191.

55. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat. Rev. Genet.** 2006, **7**, 606-619.

56. Lee, J.M.; Hanson, J.M.; Chu, W.A.; Johnson, J.A. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. *J. Biol. Chem.** 2001, **276**, 20011-20016.

57. Kang, K.W.; Lee, S.J.; Park, J.W.; Kim, S.G. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. *Mol. Pharmacol.** 2002, **62**, 1001-1010.

58. Hyde, R.; Hajduch, E.; Powell, D.J.; Taylor, P.M.; Hundal, H.S. Ceramide down-regulates System A amino acid transport and protein synthesis in rat skeletal muscle cells. *FASEB J.** 2005, **19**, 461-463.

59. Park, I.N.; Cho, I.J.; Kim, S.G. Ceramide negatively regulates glutathione S-transferase gene transactivation via repression of hepatic nuclear factor-1 that is degraded by the ubiquitin proteasome system. *Mol. Pharmacol.** 2004, **65**, 1475-1484.

60. Sekine, O.; Nishio, Y.; Egawa, K.; Nakamura, T.; Maegawa, H.; Kashiwagi, A. Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. *J. Biol. Chem.** 2002, **277**, 36631-36639.
61. Ko, M.S.; Lee, S.J.; Kim, J.W.; Lim, J.W.; Kim, S.G. Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction. Drug Metab. Dispos. 2006, 34, 1353-1360.

62. Nakanishi, H.; Brewer, K.A.; Exton, J.H. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1993, 268, 13-16.

63. Huang, H.C.; Nguyen, T.; Pickett, C.B. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 2002, 277, 42769-42774.

64. Li, B.; Wang, X.; Rasheed, N.; Hu, Y.; Boast, S.; Ishii, T.; Nakayama, K.; Nakayama, K.I.; Goff, S.P. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev. 2004, 18, 1824-1837.

65. Gineste, R.; Sirvent, A.; Paumelle, R.; Helleboid, S.; Aquilina, A.; Darteil, R.; Hum, D.W.; Fruchart, J.C.; Staels, B. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. 2008, 22, 2433-2447.

66. Frankenberg, T.; Miloh, T.; Chen, F.Y.; Ananthanarayan, M.; Sun, A.Q.; Balasubramaniyan, N.; Arias, I.; Setchell, K.D.; Suchy, F.J.; Shneider, B.L. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 2008, 48, 1896-1905.

67. Yu, R.; Chen, C.; Mo, Y.Y.; Hebbar, V.; Owuor, E.D.; Tan, T.H.; Kong, A.N. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J. Biol. Chem. 2000, 275, 39907-39913.

68. Keum, Y.S.; Owuor, E.D.; Kim, B.R.; Hu, R.; Kong, A.N. Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharm. Res. 2003, 20, 1351-1356.

69. Shen, G.; Hebbar, V.; Nair, S.; Xu, C.; Li, W.; Lin, W.; Keum, Y.S.; Han, J.; Gallo, M.A.; Kong, A.N. Regulation of Nrf2 transactivation domain activity. The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein. J. Biol. Chem. 2004, 279, 23052-23060.

70. Yu, R.; Lei, W.; Mandlekar, S.; Weber, M.J.; Der, C.J.; Wu, J.; Kong, A.N. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem. 1999, 274, 27545-27552.

71. Yu, R.; Mandlekar, S.; Lei, W.; Fahl, W.E.; Tan, T.H.; Kong, A.N. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J. Biol. Chem. 2000, 275, 2322-2327.

72. Roy, S.K.; Hu, J.; Meng, Q.; Xia, Y.; Shapiro, P.S.; Reddy, S.P.; Platianis, L.C.; Lindner, D.J.; Johnson, P.F.; Pritchard, C.; Pages, G.; Pouyssegur, J.; Kalvakolanu, D.V. MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc. Natl. Acad. Sci. USA 2002, 99, 7945-7950.

73. Salmenpera, P.; Hamalainen, S.; Hukkanen, M.; Kankuri, E. Interferon-gamma induces C/EBP beta expression and activity through MEK/ERK and p38 in T84 colon epithelial cells. Am. J. Physiol. Cell Physiol. 2003, 284, C1133-C1139.
74. Gomez-Santos, C.; Barrachina, M.; Gimenez-Xavier, P.; Dalfo, E.; Ferrer, I.; Ambrosio, S. Induction of C/EBP beta and GADD153 expression by dopamine in human neuroblastoma cells. Relationship with alpha-synuclein increase and cell damage. *Brain Res. Bull.* **2005**, *65*, 87-95.

75. Chiang, J.Y. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. *Expert Opin. Drug Metab. Toxicol.* **2009**, *5*, 137-147.

76. Han, S.; Li, T.; Ellis, E.; Strom, S.; Chiang, J.Y. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. *Mol. Endocrinol.* **2010**, *24*, 1151-1164.

77. Ktistaki, E.; Talianidis, I. Modulation of hepatic gene expression by hepatocyte nuclear factor 1. *Science* **1997**, *277*, 109-112.

78. Jung, D.; Kullak-Ublick, G.A. Hepatocyte nuclear factor 1 alpha: A key mediator of the effect of bile acids on gene expression. *Hepatology* **2003**, *37*, 622-631.

79. Wang, B.; Cai, S.R.; Gao, C.; Sladek, F.M.; Ponder, K.P. Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver. *Hepatology* **2001**, *34*, 979-989.

80. Kuo, C.J.; Conley, P.B.; Chen, L.; Sladek, F.M.; Darnell, J.E., Jr.; Crabtree, G.R. A transcriptional hierarchy involved in mammalian cell-type specification. *Nature* **1992**, *355*, 457-461.

81. Moller, D.E.; Xia, C.H.; Tang, W.; Zhu, A.X.; Jakubowski, M. Human rsk isoforms: cloning and characterization of tissue-specific expression. *Am. J. Physiol.* **1994**, *266*, C351-359.

82. Zhao, Y.; Bjorbaek, C.; Moller, D.E. Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases. *J. Biol. Chem.* **1996**, *271*, 29773-29779.

83. Lee, S.J.; Kim, S.G. Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation. *Mol. Pharmacol.* **2006**, *69*, 385-396.

84. Wiegand, H.; Wagner, A.E.; Boesch-Saadatmandi, C.; Kruse, H.P.; Kulling, S.; Rimbach, G. Effect of dietary genistein on Phase II and antioxidant enzymes in rat liver. *Cancer Genomics Proteomics* **2009**, *6*, 85-92.

85. Froyen, E.B.; Reeves, J.L.; Mitchell, A.E.; Steinberg, F.M. Regulation of phase II enzymes by genistein and daidzein in male and female Swiss Webster mice. *J. Med. Food.* **2009**, *12*, 1227-1237.

86. Hanet, N.; Lancon, A.; Delmas, D.; Jannin, B.; Chagnon, M.C.; Cherkaoui-Malki, M.; Latruffe, N.; Artur, Y.; Heydel, J.M. Effects of endocrine disruptors on genes associated with 17beta-estradiol metabolism and excretion. *Steroids* **2008**, *73*, 1242-1251.

87. Chen, C.Y.; Jang, J.H.; Li, M.H.; Surh, Y.J. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. *Biochem. Biophys. Res. Commun.* **2005**, *331*, 993-1000.

88. Canistro, D.; Bonamassa, B.; Pozzetti, L.; Sapone, A.; Abdel-Rahman, S.Z.; Biagi, G.L.; Paolini, M. Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. *Food Chem. Toxicol.* **2009**, *47*, 454-461.

89. Kweon, S.H.; Song, J.H.; Kim, T.S. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. *Biochem. Biophys. Res. Commun.* **2010**, *395*, 104-110.
90. Kim, Y.W.; Zhao, R.J.; Park, S.J.; Lee, J.R.; Cho, I.J.; Yang, C.H.; Kim, S.G.; Kim, S.C. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. *Br. J. Pharmacol.* 2008, 154, 165-173.

91. Kim, Y.W.; Kang, H.E.; Lee, M.G.; Hwang, S.J.; Kim, S.C.; Lee, C.H.; Kim, S.G. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2009, 296, G372-G381.

92. Kim, Y.W.; Kim, Y.M.; Yang, Y.M.; Kay, H.Y.; Kim, W.D.; Lee, J.W.; Hwang, S.J.; Kim, S.G. Inhibition of LXRalpha-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation. *Antioxid. Redox Signal.* 2010, EPub ahead of print.

93. Kim, Y.W.; Lee, S.M.; Shin, S.M.; Hwang, S.J.; Brooks, J.S.; Kang, H.E.; Lee, M.G.; Kim, S.C.; Kim, S.G. Efficacy of sauchinone as a novel AMPK-activating lignan for preventing iron-induced oxidative stress and liver injury. *Free Radic. Biol. Med.* 2009, 47, 1082-1092.

94. Min, H.J.; Won, H.Y.; Kim, Y.C.; Sung, S.H.; Byun, M.R.; Hwang, J.H.; Hong, J.H.; Hwang, E.S. Suppression of Th2-driven, allergen-induced airway inflammation by sauchinone. *Biochem. Biophys. Res. Commun.* 2009, 385, 204-209.

95. Han, K.Y.; Yang, D.; Chang, E.J.; Lee, Y.; Huang, H.; Sung, S.H.; Lee, Z.H.; Kim, Y.C.; Kim, H.H. Inhibition of osteoclast differentiation and bone resorption by sauchinone. *Biochem. Pharmacol.* 2007, 74, 911-923.

96. Jeong, G.S.; Lee, D.S.; Li, B.; Byun, E.; Kwon, D.Y.; Park, H.; Kim, Y.C. Protective effect of sauchinone by upregulating heme oxygenase-1 via the P38 MAPK and Nrf2/ARE pathways in HepG2 cells. *Planta Med.* 2010, 76, 41-47.

97. Kensler, T.W.; Helzlouer, K.J. Oltipraz: Clinical opportunities for cancer chemoprevention. p. J. *Cell Biochem. Suppl.* 1995, 22, 101-107.

98. Petzer, J.P.; Navamal, M.; Johnson, J.K.; Kwak, M.K.; Kensler, T.W.; Fishbein, J.C. Phase 2 enzyme induction by the major metabolite of oltipraz. *Chem. Res. Toxicol.* 2003, 16, 1463-1469.

99. Egner, P.A.; Kensler, T.W.; Prestera, T.; Talalay, P.; Libby, A.H.; Joyner, H.H.; Curphey, T.J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. *Carcinogenesis* 1994, 15, 177-181.

100. Clapper, M.L. Chemopreventive activity of oltipraz. *Pharmacol. Ther.* 1998, 78, 17-27.

101. Primiano, T.; Egner, P.A.; Sutter, T.R.; Kelloff, G.J.; Roebuck, B.D.; Kensler, T.W. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. *Cancer Res.* 1995, 55, 4319-4324.

102. Iida, K.; Itoh, K.; Kumagai, Y.; Oyasu, R.; Hattori, K.; Kawai, K.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. *Cancer Res.* 2004, 64, 6424-6431.

103. Auyeung, D.J.; Kessler, F.K.; Ritter, J.K. Mechanism of rat UDP-glucuronosyltransferase 1A6 induction by oltipraz: Evidence for a contribution of the Aryl hydrocarbon receptor pathway. *Mol. Pharmacol.* 2003, 63, 119-127.

104. Cho, I.J.; Ki, S.H.; Brooks, C., 3rd; Kim, S.G. Role of hepatitis B virus X repression of C/EBPbeta activity in the down-regulation of glutathione S-transferase A2 gene: Implications in other phase II detoxifying enzyme expression. *Xenobiotica* 2009, 39, 182-192.
105. Chan, L.M.; Lowes, S.; Hirst, B.H. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. *Eur. J. Pharm. Sci.* **2004**, *21*, 25-51.

106. Choudhuri, S.; Klaassen, C.D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. *Int. J. Toxicol.* **2006**, *25*, 231-259.

*Sample Availability:* Not Available.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).